RIO DE JANEIRO (Reuters) – Brazil’s health regulator Anvisa said on Monday it had suspended clinical trials for China’s Sinovac coronavirus vaccine, due to a “severe adverse effect” that took place on Oct. 29.
Anvisa did not provide more details, such as whether the incident took place in Brazil – where trials are being conducted – or in another country. It also did not say why news of the October event was being communicated only now.
(Reporting by Pedro Fonseca; Editing by Tom Hogue)
